The position of invasive breast tumor in relation to fibroglandular and adipose tissue was assessed in this retrospective dynamic contrast-enhanced magnetic resonance imaging investigation of 294 patients. These tumors were found to occur predominantly at the interface between fibroglandular and adipose tissue. Background: Increasing evidence suggests adipocyte involvement in malignant breast tumor invasive front or margin. The aim of this study was to evaluate the location of invasive breast tumors in relation to fibroglandular and adipose tissue by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Patients and Methods: Pretreatment breast DCE-MRI images of 294 patients with biopsy-proven invasive breast cancer from 2008 to 2014 were studied. Invasive breast tumors were visualized as enhanced lesions in the postcontrast subtraction images. Positive identification of biopsy-confirmed invasive breast tumors on DCE-MRI images was achieved by correlation of findings from breast MRI and pathology reports. Tumor location in relation to fibroglandular and adipose tissue was investigated using precontrast T1-weighted MRI images. Results: Of 294 patients, 291 had DCE-MRI discernable invasive breast tumors located at the interface between fibroglandular and adipose tissues, regardless of the tumor size, type, receptor status, or breast composition. Conclusion: Invasive breast cancer preferably and predominantly occurs adjacent to breast adipose tissue.
Introduction
The human breast is composed mainly of fibroglandular and adipose tissue. Although breast carcinoma is a type of cancer that arises from the epithelial cells that line the lobules and terminal ducts of breast glandular tissue, 1 it develops in a complex tissue environment and depends on bidirectional communication with other tissues for tumor initiation and progression. 2 Adipose tissue is of special interest because it is one of the major components in the breast. Increasing evidence suggests adipocyte involvement in the breast tumor invasive front, presumably due to the close proximity of adipose and glandular tissue. 3 An earlier histology study of 310 patients with invasive ductal carcinoma of the breast demonstrated that adipose tissue was present in the breast tumor margin of 245 patients. 4 While some studies have reported cross-talk between breast tumor cells and peritumoral adipocytes, 5, 6 it is not known whether this cross-talk is incidental or obligatory in breast cancer initiation and development. The investigation into the breast tumor microenvironment has mainly been focused on nonadipocyte components. 7 Overall adiposity plays an important role in many epithelial malignancies, including breast cancer, as manifested by increased breast cancer incidence rates in overweight/obese women. [8] [9] [10] Obesity is associated with systemic effects, including insulin resistance, altered hormone signaling, and high circulating levels of proinflammatory mediators that favor tumor initiation and progression. [11] [12] [13] However, the local effect of adipocytes in breast cancer has been less explored. In addition, the breast is a unique and 1 Division of Cancer Imaging Research, Russell H. Morgan Department of Radiology and Radiological Sciences dynamic organ. Breast density, a measurement of the fibroglandular/adipose tissue composition, fluctuates throughout an adult woman's life as a result of factors such as weight gain, pregnancy, lactation, and mammary-and age-related lobular involution. There has been a long-standing interest in the relationship between breast cancer and involution, [14] [15] [16] [17] [18] during which breast fibroglandular tissue is replaced by adipose tissue. We aimed to evaluate the location of invasive breast tumors in relation to fibroglandular and adipose tissue using dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) in this retrospective study. DCE-MRI is an ideal tool with which to investigate the macroscopic interaction between adipose tissue and breast tumors. Malignant breast tumors are identified on postcontrast subtraction images by a rapid enhancement resulting from their increased vascularity, while adipose and fibroglandular tissue can be differentiated in the corresponding precontrast T1-weighted images.
Methods

Patient Selection
This retrospective DCE-MRI study of invasive breast cancer patients was approved by our institutional review board under the Health Insurance Portability and Accountability Act. The requirement for consent was waived. Breast MRI images and reports acquired from October 2008 to December 2014 at our outpatient center were reviewed consecutively using the Picture Archiving and Communication System (PACS) database. Those with a biopsyproven unilateral invasive breast cancer diagnosis or suspicious lesions were identified from the MRI reports. These patients' electronic medical records were subsequently reviewed to confirm the presence of an invasive breast cancer diagnosis. Only those who had an MRI performed before any breast cancererelated therapeutic intervention were included in the current study. Women with a history of breast surgery and/or cancer of any organs were excluded. This study was limited to invasive breast cancer only. Women with a diagnosis of ductal carcinoma-in-situ were also excluded.
Breast DCE-MRI Image Acquisition Techniques
Clinical breast DCE-MRI acquisition techniques have evolved over the years at our institution. Early images were acquired with relatively thicker slices and without fat saturation in order to achieve a high temporal resolution. New techniques that allowed thinner slices with fat saturation were gradually adapted after 2014.
Three-dimensional axial DCE-MRI images without fat saturation that covered both breasts entirely were acquired with the following parameters: TR/TE, 4.2/2.1 ms; flip angle, 10 ; slice thickness, 2.5 to 2.7 mm; and in-plane resolution of 0.33 mm Â 0.33 mm to 0.67 mm Â 0.67 mm at a temporal resolution of 15 seconds per acquisition. Gadobenate dimeglumine (MultiHance, Bracco Imaging) was administered intravenously at a dose of 0.1 mmol/kg and an injection rate of 2 mL/s using a power injector (Spectris Solaris MR Injection System, Medrad). DCE-MRI was performed on one of the 1.5 T Achieva (Philips Medical System), 3 T Intera (Philips Medical System), or 3 T TrioTim (Siemens) MRI scanners using bilateral phased-array breast coils with patients lying in the prone position. Three-dimensional axial DCE-MRI images with fat saturation that covered both breasts entirely were acquired with the following parameters: TR 4.9 to 7.8 ms, TE 2.5 to 4.8 ms; flip angle, 12 ; slice thickness, 0.5 to 1.5 mm; and in-plane resolution 0.66 mm Â 0.66 mm to 0.91 mm Â 0.91 mm at a temporal resolution of 16 to 93 seconds per acquisition on the 3 T Intera (Philips Medical System), or 3 T TrioTim (Siemens) MRI scanners using bilateral phased-array breast coils with patients lying in the prone position. Gadobenate dimeglumine (MultiHance, Bracco Imaging) was administered intravenously at a dose of 0.1 mmol/kg and an injection rate of 2 mL/, using a power injector (Spectris Solaris MR Injection System, Medrad).
Breast Tumor Identification
Enhanced breast lesions were visually identified on the postcontrast subtraction images after the contrast enhancement reached a plateau, which occurred about 1 to 2 minutes after the administration of the contrast agent. Findings from the official breast MRI reports and pathology reports were used to confirm whether these enhanced lesions were indeed the pathology-proven invasive breast tumors.
Location of the Breast Tumor in Relation to Adipose Tissue
Breast fibroglandular and adipose tissues were differentiated by their strong intensity difference on the precontrast T1-weighted images. Adipose tissue appeared bright and fibroglandular tissue appeared dark on the T1-weighted images without fat saturation. The contrast between adipose and fibroglandular tissue is reversed on T1-weighted images with fat saturation. The breast tumor position in relation to adipose tissue was visually assessed by overlaying the contrast-enhanced MRI images on the corresponding T1-weighted precontrast images. Image analysis and visualization were performed in Fiji/ImageJ. 19, 20 Breast Density Assessment and the Thickness of the Upper Abdominal Adipose Layer Three-dimensional MRI breast density was calculated from the contralateral breast with no tumor from the precontrast T1-weighted images without fat saturation as described elsewhere. 21 Briefly, bright fatty tissue and the entire breast were segmented by thresholding separately after the correction of image intensity bias artifacts due to magnetic field heterogeneity. Total voxel counts of the fatty tissue and the entire breast were calculated by an automated macro. The percentage of fatty tissue density was calculated as the percentage of total voxel counts occupied by the fatty tissues divided by that of the entire breast. The MRI percent breast density was calculated as the remaining percentage of the fatty tissue. 21 The thickness of the upper abdominal adipose layer (UAAL) was measured on the T1-weighted precontrast axial images immediately below the breasts. This thickness was used as a surrogate marker for body adiposity because of a lack of body mass index information in this retrospective study. 21 
Results
Patient Selection Characteristics
Breast DCE-MRI was performed in our institution for high-risk screening, 22 evaluation of a suspicious lesion/lump, and treatment
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Breast Cancer and Fibroglandular and Adipose Tissue planning after a breast cancer diagnosis, all at the discretion of treating physicians. A total of 294 consecutive patients diagnosed with unilateral invasive breast cancer with pretreatment breast DCE-MRI performed from October 2008 to December 2014 in our outpatient center were identified by MRI reports and the corresponding medical records. MRI breast density measurements for these patients have been previously reported. 21 The indication for breast DCE-MRI was for the evaluation of disease extent and treatment planning after receipt of a biopsy-proven invasive breast cancer diagnosis for a majority of these patients (276, 94%). Fifteen of the 294 patients had DCE-MRI performed to evaluate suspicious breast lesions/lumps or bloody discharge and were subsequently diagnosed with invasive breast cancer. The remaining 2 patients were diagnosed with invasive breast cancer during their routine high-risk DCE-MRI screening. Breast DCE-MRI was performed without fat saturation in 278 patients and with fat saturation in 16 patients.
Patient Age, Body Adiposity, and Breast Density
The age of these patients ranged from 25 to 80 years. The thickness of the UAAL, a surrogate marker for body adiposity, ranged from 1 to 37 mm. The MRI breast density of these patients was calculated from the T1-weighted precontrast images, as described elsewhere. 21 The density ranged from very dense at 80.7% to very fatty at 3.2%. Patient age, UAAL thickness, and MRI breast density distribution are listed in Table 1 .
Breast Cancer Receptor Status
Immunohistochemical studies indicated that 69.4% of these tumors were estrogen and/or progesterone receptor positive, 5.4% were human epidermal growth factor receptor 2 (HER-2) positive only, 13.6% were estrogen and/or progesterone positive and HER-2 positive, and 11.2% were triple negative (estrogen and progesterone receptor negative and HER-2 negative). 23 Receptor status was not available in the medical records for one patient. 
Breast Cancer Stage
Breast Cancer Type
Breast cancer type was retrieved from surgical or biopsy pathology reports. The dominant breast cancer type was invasive ductal carcinoma, followed by invasive mammary carcinoma (a mixture of invasive ductal and lobular carcinomas) and infiltrating lobular carcinoma. Cancer type information was not available for 1 patients. Another patient was diagnosed with a high-grade neoplasm with neuroendocrine differentiation. Breast cancer type distribution is listed in Table 2 .
Breast Tumor Location in Relation to Adipose Tissue
Visual inspection of the enhanced MRI images demonstrated that 291 of 294 patients had invasive breast tumors located at the interface between fibroglandular and adipose (IFFA) tissues, regardless of the tumor size, tumor type, receptor status, or breast density. The remaining 3 patients had tumors that were too small to be visualized on the enhanced MRI images in the presence of strong background enhancement.
Specifically, invasive breast tumors were identified at the IFFA in patients with unifocal disease, regardless of tumor size, receptor status, type, or breast density (Figure 1) . Moreover, unifocal breast tumors ( Figure 2A) were identified surrounded by adipose tissue apart from the main fibroglandular parenchyma ( Figure 2B ) in 9 patients. Each breast tumor was also identified at the IFFA in all 22 patients with multifocal or multicentric disease (Figure 3 ). In addition, invasive breast tumor location at the IFFA was independent of the DCE-MRI image acquisition protocols. Tumor location at the IFFA was also confirmed in all 19 patients whose DCE-MRI images were acquired with fat saturation (Figure 4) . In summary, 100% of the DCE-MRI conspicuous invasive breast tumors in the current study population were observed at the IFFA. Adipose Tissue Expansion Pattern Figure 5 shows the effect of body adiposity on adipose tissue expansion in 4 invasive breast cancer patients aged 31 to 32 years. The top row shows the increasing thickness of the UAAL of these patients. The middle row shows that as the thickness of the UAAL increased, subcutaneous adipose tissue expanded inward from the breast periphery, and retromammary adipose tissue expanded outward from the chest wall. The expansion of adipose tissue is accompanied by the concurrent regression of fibroglandular tissue. Eventually, a patient with an 18 mm thick UAAL had almost entirely fatty breasts at age 32. Figure 6 shows the effect of age on adipose tissue expansion in 4 invasive breast cancer patients with the same thickness of UAAL of 10 mm in women aged 27 to 69. The middle row of Figure 6 demonstrates a similar adipose tissue expansion pattern as that in Figure 5 . Figures 5 and 6 show that the expansion of adipose tissue and the regression of the fibroglandular tissue (ie, breast involution) can be mediated by either body adiposity or age. Invasive breast tumors were predominantly observed at the IFFA tissue, where the expansion of adipose tissue and the regression of the fibroglandular tissue occurred concurrently.
Discussion
Our results demonstrated that invasive breast tumors preferably and predominantly occurred at the IFFA. This finding is in accordance with an earlier histology study of 310 patients, which demonstrated that adipose tissue was present in 79.0% of breast tumor margins. 4 However, breast DCE-MRI images have the advantage of providing a view of the entire tumor and its surroundings noninvasively, without disrupting the native tumor The degree of complete involution is associated with a reduced risk of breast cancer. 17 We hypothesized that the IFFA is where involution, the expansion of adipose tissue, and the regression of fibroglandular tissue happens. Breast carcinoma carcinogenesis is a multiphase malignant transformation of the normal breast epithelial cells 26 from hyperplasia, to atypia, to in-situ malignancy, to invasive malignancy. We hypothesized that aberrations in involution may contribute directly to the malignant transformation of normal breast cells in addition to the reported benign breast conditions. 27 Furthermore, both excessive adiposity 10, 28 and postlactation involution 18, 29, 30 are associated with elevated proinflammation mediator expression, which is conducive to tumor formation. We hypothesized that aberration in involution produces the breast cancer seeds that grow in the fertile adipose soil at the IFFA. Breast cancer rates increase with age, as breast tissue undergoes atrophy due to lobular involution.
14 Incidentally, fewer pregnancyrelated breast cancers are diagnosed during pregnancy, 31 when extensive breast glandular cell differentiation and growth occurrs.
29
More pregnancy-associated breast cancers are diagnosed 7 to 24 Collectively, this suggests a strong link between involution and breast cancer. Unfortunately, our understanding of breast involution, particularly the age-related lobular involution process, is limited. Our discovery demonstrates the potential importance of adipose tissue in the development of breast cancer. More research is needed to understand the breast involution process and the cross-talk mechanism between breast epithelial cells and adipocytes, which may enhance the malignant transformation of normal breast cells. A greater understanding of these processes may enable the development of new breast cancer prevention, detection, and treatment approaches.
Clinical Practice Points
Being overweight or obese after menopause is linked to a higher risk of breast cancer. Increasing evidence suggests adipocyte involvement in malignant breast tumor invasive front or margin. Breast cancer predominately and preferably occurs adjacent to breast adipose tissue, regardless of tumor size, subtype, or breast composition in this retrospective DCE-MRI investigation of 294 patients. Careful assessment of the interface between adipose and glandular tissues on imaging is warranted during screening, detection and characterization of breast cancer. Understanding of how adipocytes promote breast cancer may provide new insights to breast cancer prevention, detection, and treatment. 
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